2020… Ah, what a ride.
And no, this is not another text piece joining the chorus of weeping, complaining, and interpreting how the Covid-19 pandemic has devastated drug developers – except those who had an approved antiviral drug available that had some effect against SARS-CoV2.
And of course, except those who suddenly fell in love with drug repurposing and actually identified a marketed drug (perhaps an almost forgotten one), or a discontinued drug candidate from their freezers, that had an antiviral effect in the lab. (Those of us who were around when HIV was discover
ed will remember that it is only moderately difficult. Translational development? Thats for later.)
During this Covid year drug repurposing enjoyed a moderate amount of media attention until the rush for vaccines overtook everything else. Many candidates were rushed into clinical trials before the molecular biology of SARS-CoV2 and the natural history of the Covid-19 disease were properly understood. (See the critical paper about the Drug Re
Did H.M. Pharma Consultancy profit from this, or is it barely staggering along as so many others? Actually, our business was hardly affected either way. Our agile little entity continued along existing lines, with drug repurposing,
patenting, the double-edged pharmacology of reactive oxygen species and its European Union H2020 projects. We fully intend to be part of the rush that will soon set in during this new decade: Covid-19 has brought not only ruin and death but also a tremendous acceleration of overdue digital developments had been merely tottering along. There is so much information out there that is mostly ignored!
As an opener, this blog will share international patent applications from the rare disease area that we are identifying during our constant surveillance of the PCT space. (As we have shown, information from the freely accessible intellectual property space can reach the public hundreds of days ahead of peer review papers, if at all; see here.) By about mid-month you will see last month’s documents listed here; starting not in the New Year but now. – Stay tuned!